Smooth muscle function recovery was also reviewed [3,4] (i.e., sphincter dysfunction (pupil [86], lower esophageal and pyloric sphincter [92,93,94,95,96,97,98,99], urethral sphincter [100,101,102], intestinal adaptation, and lesion recovery [103,104])
First, the FDA has not granted retatrutide Breakthrough Therapy designation as of May 2026, which means there is no built-in mechanism for an accelerated review
For people seeking a non-injectable route with stronger evidence than simple fiber, Motus (oral) presents a trial-backed middle option
Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses
Before DSAI, it was the fight over the creation of Hopkins police force
Brand-name medications come in pre-filled injection pens that are convenient and easy to use